Autism Drugmaker Raises $6.5 Million
Curemark, a Rye, N.Y.-based developer of drugs that address certain gastrointestinal and pancreatic secretory deficiencies, has raised $6.5 million in Series A funding. No investor information was disclosed. The company's lead candidate focuses on autism, and will soon enter Phase III clinical trials.
10 August 2009•2 mins read
